Zydus Lifesciences gets first Canadian nod for smoking deterrent varenicline tablets

Zydus Lifesciences has received its first-ever notice of compliance (NOC) from Health Canada for ZDS-varenicline tablets in 0.5 mg and 1 mg strengths.The tablets are indicated for smoking cessation and act as partial agonists of nicotinic acetylcholine receptors, helping reduce nicotine cravings while blocking its pleasurable effects. Zydus will manufacture the product at its SEZ facility in Ahmedabad.

According to IQVIA data for the 12 months ended December 2024, the Canadian market for varenicline tablets was valued at CAD 15 million annually. With this approval, Zydus makes its debut in the Canadian prescription drug market, expanding its global regulatory footprint.

Shares of Zydus Lifesciences ended 1.5% in the green in the session on  Thursday, August 7. The stock has fallen 2.8% in the year so far.In July, the company received tentative approval for a cancer treatment drug from the US drug regulator. The pharma company, in an exchange filing, said that it has received tentative approval from the United States Food and Drug Administration (FDA) for ibrutinib tablets 140 mg, 280 mg, and 420 mg variants.

Also Read: Crompton Greaves Q1 profit drops 19.4% on weak consumer demand